In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs

[1]  S. Fox,et al.  High resolution melting for mutation scanning of TP53 exons 5–8 , 2007, BMC Cancer.

[2]  J. Meixensberger,et al.  Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis , 2007, Clinical Cancer Research.

[3]  P. Canoll,et al.  Convection-enhanced delivery in the treatment of malignant glioma , 2006, Neurological research.

[4]  Yuri Kotliarov,et al.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. , 2006, Cancer cell.

[5]  Erwin G. Van Meir,et al.  Genomic Alterations in Human Malignant Glioma Cells Associate with the Cell Resistance to the Combination Treatment with Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand and Chemotherapy , 2006, Clinical Cancer Research.

[6]  Andreas Untergasser,et al.  Preclinical Differentiation between Apparently Safe and Potentially Hepatotoxic Applications of TRAIL Either Alone or in Combination with Chemotherapeutic Drugs , 2006, Clinical Cancer Research.

[7]  V. Yong,et al.  Human Astrocytes Are Resistant to Fas Ligand and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis , 2006, The Journal of Neuroscience.

[8]  Robert A Nagourney,et al.  Ex vivo programmed cell death and the prediction of response to chemotherapy , 2006, Current treatment options in oncology.

[9]  Z. Ram,et al.  Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial , 2006, Acta Neurochirurgica.

[10]  L. Ricci-Vitiani,et al.  Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. , 2005, Cancer research.

[11]  J. Beijnen,et al.  Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra®, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours , 2005, British Journal of Cancer.

[12]  A. Kaye,et al.  Caspase 8 is absent or low in many ex vivo gliomas , 2005, Cancer.

[13]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[14]  P. Johnston,et al.  Molecular mechanisms of drug resistance , 2005, The Journal of pathology.

[15]  M. Berger,et al.  Convection-Enhanced Delivery of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand with Systemic Administration of Temozolomide Prolongs Survival in an Intracranial Glioblastoma Xenograft Model , 2004, Cancer Research.

[16]  I. Jeremias,et al.  Cell death induction by betulinic acid, ceramide and TRAIL in primary glioblastoma multiforme cells , 2004, Acta Neurochirurgica.

[17]  Boris Zhivotovsky,et al.  DNA damage-induced apoptosis , 2004, Oncogene.

[18]  P. Ekert,et al.  Caspase‐8 levels affect necessity for mitochondrial amplification in death ligand‐induced glioma cell apoptosis , 2004, Molecular carcinogenesis.

[19]  I. Ishida,et al.  Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2 , 2004, Cell Death and Differentiation.

[20]  A. Thorburn,et al.  Death receptor-induced cell killing. , 2004, Cellular signalling.

[21]  T. Batchelor,et al.  Determination of procarbazine in human plasma by liquid chromatography with electrospray ionization mass spectrometry. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[22]  Y Iwadate,et al.  Promising survival for patients with glioblastoma multiforme treated with individualised chemotherapy based on in vitro drug sensitivity testing , 2003, British Journal of Cancer.

[23]  B. Pyrzyńska,et al.  TRAIL Triggers Apoptosis in Human Malignant Glioma Cells Through Extrinsic and Intrinsic Pathways , 2003, Brain pathology.

[24]  W. Roa,et al.  X-linked inhibitor regulating TRAIL-induced apoptosis in chemoresistant human primary glioblastoma cells. , 2003, Clinical and investigative medicine. Medecine clinique et experimentale.

[25]  B. Turowski,et al.  Cisplatin tumor concentrations after intra‐arterial cisplatin infusion or embolization in patients with oral cancer , 2003, Clinical pharmacology and therapeutics.

[26]  H. Naganuma,et al.  A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents , 2003, British Journal of Cancer.

[27]  K Kurosu,et al.  Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer , 2003, British Journal of Cancer.

[28]  Y. Figenschau,et al.  Tumor necrosis factor-related apoptosis-inducing ligand induces apoptosis in human articular chondrocytes in vitro. , 2002, Biochemical and biophysical research communications.

[29]  F. Beguinot,et al.  Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Death-inducing Signaling Complex and Its Modulation by c-FLIP and PED/PEA-15 in Glioma Cells* , 2002, The Journal of Biological Chemistry.

[30]  S. Fulda,et al.  Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression , 2002, Oncogene.

[31]  L. Stewart,et al.  Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials , 2002, The Lancet.

[32]  A. Kraft,et al.  Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells , 2002, Oncogene.

[33]  D. Ashley,et al.  Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells , 2001, Oncogene.

[34]  M. Weller,et al.  CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release , 2001, Oncogene.

[35]  T. Kuroki,et al.  A protective role of PKCepsilon against TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in glioma cells. , 2001, Biochemical and biophysical research communications.

[36]  S. S. Strom,et al.  Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions , 2001, Nature Medicine.

[37]  P. Hersey,et al.  Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  Erwin G. Van Meir,et al.  Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. , 2001, Cancer research.

[39]  I. Bechmann,et al.  Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL) , 2000, The Lancet.

[40]  S. Schmerber,et al.  Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. , 2000, International journal of oncology.

[41]  Mian Wu,et al.  Induction of apoptosis in glioma cell lines by TRAIL/Apo‐2l , 2000, Journal of neuroscience research.

[42]  S. Strom,et al.  Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand , 2000, Nature Medicine.

[43]  W. Cavenee,et al.  Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. , 2000, Cancer research.

[44]  E. Bröcker,et al.  Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. , 2000, Cancer research.

[45]  P. Beale,et al.  Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies , 1999, British Journal of Cancer.

[46]  G Brockhoff,et al.  Use of a mechanical dissociation device to improve standardization of flow cytometric cytokeratin DNA measurements of colon carcinomas. , 1999, Cytometry.

[47]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[48]  M. Weller,et al.  APO2 ligand: a novel lethal weapon against malignant glioma? , 1998, FEBS letters.

[49]  M. Peter,et al.  Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.

[50]  M. Peter,et al.  Cytotoxicity‐dependent APO‐1 (Fas/CD95)‐associated proteins form a death‐inducing signaling complex (DISC) with the receptor. , 1995, The EMBO journal.

[51]  W. Kamps,et al.  Vincristine pharmacokinetics and response to vincristine monotherapy in an up-front window study of the Dutch Childhood Leukaemia Study Group (DCLSG). , 2005, European journal of cancer.

[52]  C. Hawkins.  TRAIL and malignant glioma. , 2004, Vitamins and hormones.

[53]  K. Sugiyama,et al.  Penetration of etoposide into human malignant brain tumors after intravenous and oral administration , 2004, Cancer Chemotherapy and Pharmacology.

[54]  S. Urien,et al.  Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients , 2004, Cancer Chemotherapy and Pharmacology.

[55]  N. Bleehen,et al.  Clinical pharmacokinetics of oral CCNU (Lomustine) , 2004, Cancer Chemotherapy and Pharmacology.

[56]  Michael Weller,et al.  Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo , 2002, Nature Medicine.

[57]  David E. Anderson,et al.  Changes in the immunologic phenotype of human malignant glioma cells after passaging in vitro. , 2002, Clinical immunology.

[58]  I. Whittle,et al.  Platinum distribution in malignant glioma following intraoperative intravenous infusion of carboplatin. , 1999, British journal of neurosurgery.

[59]  I. Krantz,et al.  KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene , 1997, Nature Genetics.

[60]  T. Blaschke,et al.  Pharmacokinetics of high-dose oral CCNU in bone marrow transplant patients , 1996, Cancer Chemotherapy and Pharmacology.